Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (745K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
BURNS JJ, YU TF, RITTERBAND A, PEREL JM, GUTMAN AB, BRODIE BB. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther. 1957 Mar;119(3):418–426.[PubMed]
KERSLEY GD, COOK ER, TOVEY DC. Value of uricosuric agents and in particular of G. 28 315 in gout. Ann Rheum Dis. 1958 Sep;17(3):326–333.[PMC free article][PubMed]
LANSBURY J, HAUT DD. Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity. Am J Med Sci. 1956 Aug;232(2):150–155.[PubMed]
OGRYZLO MA, HARRISON J. Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis. 1957 Dec;16(4):425–437.[PMC free article][PubMed]
SEEGMILLER JE, GRAYZEL AI. Use of the newer uricosuric agents in the management of gout. JAMA. 1960 Jul 9;173:1076–1080.[PubMed]
YU TF, BURNS JJ, GUTMAN AB. Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum. 1958 Dec;1(6):532–543.[PubMed]
Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press